Summary

Researchers in Egypt conducting a prospective, Phase 3, randomized trial found no significant difference in time to progression or overall survival in patients with stage IV advanced and metastatic non—small cell lung cancer (NSCLC) who received either gemcitabine or best supportive care after induction therapy. Findings were displayed in a poster presentation.